Tekmira and Collaborators Present Data at the AACRMeeting on Tekmira's Lead Oncology Product, TKM-PLK1, and an Oncology Product Candidate Targeting Kinase WEE1

Tekmira Pharmaceuticals Corporation TKMR announced today that it will present additional data on its lead oncology product candidate, TKM-PLK1, at the AACR Annual Meeting 2011 taking place April 2-6, 2011 in Orlando, Florida. In addition, Tekmira's collaboration partner, the National Cancer Institute, will present a poster that includes anti-tumor activity data from silencing a promising cell cycle kinase target enabled by Tekmira's lipid nanoparticle delivery technology. In a presentation entitled, "Preclinical Characterization of TKM-080301, a Lipid Nanoparticle Formulation of Small Interfering RNA Directed Against Polo-like Kinase 1," Tekmira will present data supporting the development of TKM-PLK1 as a treatment for cancer. The presentation outlines the rational design of siRNA against polo-like kinase 1, a protein involved in tumor cell proliferation and an important oncology target. Inhibition of PLK1 prevents the tumor cell from completing cell division, resulting in cancer cell death.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!